CytoDel
New York, US · Delaware corporation · 1 known investors
Biopharmaceutical company using molecular biology to produce recombinant derivatives of botulinum neurotoxin for customized applications.
Founders & leadership
CW
Charles WeissNamed on SEC filing
AG
Andre GudgerNamed on SEC filing
PA
Philip A. BandNamed on SEC filing
MF
Margery FischbeinNamed on SEC filing
Investors · 1
Reported raises · per SEC filings
Form D private placements$4.1M disclosed across 2 rounds · 2017–2018
▶$3.9MraisedJan 2018 · 11 investors · BiotechnologyRule 506(b)
▶$3.9MraisedJan 2018 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Charles WeissDirector
- Andre GudgerDirector
- Philip A. BandExecutive Officer, Director
- Margery FischbeinDirector
- Offering amount
- $6.1M
- Amount sold
- $3.9M
- Minimum investment
- $50K
- First sale
- Jan 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$150KraisedApr 2017 · 2 investors · PharmaceuticalsRule 506(b)
▶$150KraisedApr 2017 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Philip A. BandExecutive Officer, Director
- Offering amount
- $400K
- Amount sold
- $150K
- Minimum investment
- $50K
- First sale
- Mar 2017
- Incorporated
- Limited Liability Company, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does CytoDel do?
- Biopharmaceutical company using molecular biology to produce recombinant derivatives of botulinum neurotoxin for customized applications.
- Who are CytoDel's investors?
- CytoDel's investors include Kairos Venture Investments, Llc.
- How much funding has CytoDel raised?
- CytoDel has disclosed $4.1M raised across 2 rounds.
- Where is CytoDel headquartered?
- CytoDel is headquartered in New York, US.